The tweet was deleted by the author.
But we saved everything 🙂.
Fulgent Genetics has significantly expanded its infertility next-generation sequencing (NGS) panels, adding 41 genes to the Female Infertility Panel—bringing the total to 143, including all OZEMA genes—and 17 genes to the Male Infertility Panel, which now covers 163 genes.
The company encourages pairing these expanded panels with BeaconCarrierScreening to provide a more comprehensive assessment of reproductive health. This move reflects a continuing effort to offer more inclusive genetic insights for couples facing fertility challenges.
Fulgent Genetics has pursued other areas of medical innovation in recent months. The company previously announced plans to present new data on its nano-encapsulated anti-tumor drug FID-007 at this year's ASCO meeting. This comes as Fulgent continues to expand its portfolio across both diagnostics and therapeutics.